Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain

Pediatric Blood and Cancer

Volumn 60, Issue 3, 2013, Pages 433-437

  Ruggiero, Antonio ^a   Coccia, Paola ^a   Arena, Roberta ^a   Maurizi, Palma ^a   Battista, Andrea ^a   Ridola, Vita ^a   Attinà, Giorgio ^a   Riccardi, Riccardo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Buprenorphine; Cancer pain; Children; Transdermal patch

Indexed keywords

ANTIEMETIC AGENT; BUPRENORPHINE; TRAMADOL;

ADOLESCENT; ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; CHILD; CHILD NUTRITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; MALE; NAUSEA; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PLAY; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RATING SCALE; SCHOOL CHILD; SLEEP QUALITY; VOMITING; WONG BAKER FACE PAIN RATING SCALE;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ANALGESICS, OPIOID; BUPRENORPHINE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; NEOPLASMS; PAIN;

EID: 84872472264     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24332     Document Type: Article

References (32)

1. Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003; 28: 2000-2009.
2. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96: 627-632.
3. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anesth 2005; 94: 825-834.
4. Yassen A, Olofsen E, Kan J, et al. Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res 2008; 25: 183-193.
5. Williams W, Rice KC, Weber R. Non peptide opioids: In vivo effects on the immune system. NIDA Res Monogfr 1991; 105: 404-407.
6. Gomez-Flores R, Weber R. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periacqueductal gray. Immunopharmacology 2000; 48: 145-156.
7. Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: Similar analgesic profile but different effects on immune responses. Pain 2004; 110: 385-392.
8. Ceccarelli I, de Padova AM, Fiorenzani P, et al. Single opioid administration modifies gonadal steroids in both CNS and plasma of male rats. Neuroscience 2006; 140: 929-937.
9. Bliesener N, Albrecht S, Scwager A, et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 2005; 90: 203-206.
10. Heel RC, Brogden RN, Speight TM, et al. Buprenorphine: A review of its pharmacological properties and therapeutics efficacy. Drugs 1979; 17: 81-110.
11. Filitz J, Griessinger N, Sittl R, et al. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic patients treated with transdermal buprenorphine. Eur J Pain 2006; 10: 743-748.
12. Hannah C, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63: 1999-2010.
13. Budd K. Old dog-new matrix. Br J Anaesth 2003; 90: 2-4.
14. Caplan RA, Southam M. Transdermal drug delivery and its application to pain control. In: Benedetti C, editor. Advances in pain research and therapy. New York: Raven Press; 1990. pp. 233-240.
15. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today 2004; 9: 697-703.
16. Bohme L, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patient with cronic pain. A randomised, double-blind, placebo-controlled study. Pain Clin 2003; 15: 193-202.
17. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multi center, randomized, double-blind, placebo-controller trial. Clin Ther 2003; 25: 150-168.
18. Radbruch L, Vielvoye-Kerkmeer A. Buprenorphine TDS. The clinical development rationale and results. Int J Clin Pract Suppl 2003; 133: 15-18.
19. Radbruch L. Efficacy and tolerability of buprenorphine TDS in cancer pain patients. Eur J Palliat Care 2003; 10: 13-16.
20. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: Results of a Phase III, multi center, randomised, double-blind, placebo-controlled study. Clin Ther 2004; 26: 1808-1820.
21. Attinà G, Ruggiero A, Maurizi P, et al. Transdermal buprenorphine in children with cancer-related pain. Pediatr Blood Cancer 2009; 52: 125-127.
22. Zernikow B, Schiessl C, Wamsler C, et al. Long-term pediatric opioid based pain control. Case reports. Schmerz 2005; 19: 418-425.
23. Mercadante S. Cancer pain management in children. Palliat Med 2004; 18: 654-662.
24. Goldman A, Hewitt M, Collins GS, et al. Symptoms in children/young people with progressive malignant disease: United Kingdom Children's Cancer Study Group/Pediatric Oncology Nurses Forum Survey. Pediatrics 2006; 117: 1179-1186.
25. Wolfe J, Grier HE, Klar N, et al. Symptoms and suffering at the end of life in children with cancer. N Engl J Med 2000; 342: 326-333.
26. Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Practice 2010; 10: 428-450.
27. Budd K. Buprenorphine and the transdermal system: The ideal match in pain management. Int J Clin Pract Suppl 2003; 133: 9-14.
28. Michel E, Anderson BJ, Zernikow B. Buprenorphine TTS for children, a review of the drug's clinical pharmacology. Paediatr Anaesth 2011; 21: 280-290.
29. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63: 1999-2010.
30. Griessinger N, Sittl L, Likar R. Transdernal buprenorphine in clinical practice-A post marketing surveillance study in 13179 patients. Curr Med Res Opin 2005; 21: 1147-1156.
31. Likar R., Transdermal buprenorphine in the management of persistent pain-safety aspects. Ther Clin Risk Manag 2006; 2: 115-125.
32. Finkel J, Finley A, Greco C, et al. Transdermal fentanyl in the management of children with chronic severe pain. Cancer 2005; 104: 2847-2857.